vTv Therapeutics Inc. - Class A Common Stock - Nakit Akışı (NASDAQ:VTVT)

Financials

İşletme faaliyetlerinden elde edilen nakit -18 M-19.31 M-16.02 M-19.08 M-25.31 M-25.25 M -10.41 M Yatırım faaliyetlerinden elde edilen nakit 242 K242 K-21 K4.4 M00 — Finansman faaliyetlerinden elde edilen nakit 19.47 M26.98 M14.75 M12 M52.61 M77.44 M — Serbest nakit akışı -18 M-19.31 M-16.02 M-19.08 M-25.31 M-25.25 M -10.41 M

Haberler

vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable

H.C. Wainwright, vTv Therapeutics hisse hedefini 45 dolara düşürdü

Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High?

BTIG, vTv Therapeutics için Al tavsiyesini yineledi

Evercore ISI, vTv Therapeutics hissesine alım önerisiyle başladı

Evercore ISI initiates vTv Therapeutics stock with outperform rating

BTIG, vTv Therapeutics için Al tavsiyesini yineledi, 49 dolar hedef korundu

BTIG reiterates Buy on vTv Therapeutics stock, $49 target maintained

VTv Stock: Cadisegliatin's Phase 3 CATT1 Readout Is The Next Catalyst (NASDAQ:VTVT)

vTv Therapeutics, Newsoara Biopharma ile HPP737 lisans anlaşmasını genişletti

vTv Therapeutics expands HPP737 license agreement with Newsoara Biopharma

vTv expands Newsoara license deal for PDE4 inhibitor to global rights